title: [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
abstract: Targeted therapy in lung cancer changes the prognostic and treatment of patients. MET is an oncogene including exon 14 mutations and gene amplification associated with worse prognosis. We here report the case of a 47-year-old former smoker, woman, with a stage IV lung adenocarcinoma with multiple chemotherapy failure. A MET amplification was identified and the patient consequently received crizotinib. A major response was observed after eight weeks of treatment. MET amplification screening appears to be interesting with some oncogenic-addicted tumor response rate. Those patients should be enrolled in clinical trials dedicated to tumor with MET alteration.
authors.affiliation: Service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Rabeau
authors.affiliation: Service de pathologie, IUCT-Oncopole, CHU de Toulouse, 31100 Toulouse, France.
authors.forename: I
authors.initials: I
authors.lastname: Rouquette
authors.affiliation: Clinique de l'Occitanie, 31600 Muret, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Vantelon
authors.affiliation: Service de pathologie, IUCT-Oncopole, CHU de Toulouse, 31100 Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Taranchon-Clermont
authors.affiliation: Service de pneumologie, hôpital Larrey, université Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.
authors.forename: J
authors.initials: J
authors.lastname: Mazières
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000077547:Crizotinib; D005260:Female; D005784:Gene Amplification; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009154:Mutation; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D019859:Proto-Oncogene Proteins c-met
keywords: Adénocarcinome pulmonaire; Crizotinib; Lung adenocarcinoma; MET; Targeted therapy; Thérapie ciblée